Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

EYPT Investor Alert: Levi & Korsinsky Investigates EyePoint, Inc. (EYPT) For Potential Securities Fraud

accessnewswire.com
EYPT The company's stock dropped 70% after its drug DURAVYU failed to meet the primary endpoint in a Phase 3 trial. An investigation has been launched into potential securities fraud due to alleged inadequate disclosure of trial risks.

EYPT Investor Alert: Levi & Korsinsky Investigates EyePoint, Inc. (EYPT) For Potential Securities Fraud NEW YORK CITY, NY / ACCESS Newswire / August 24, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into EyePoint, Inc. ("EyePoint, Inc.") (NASDAQ:EYPT) concerning potential violations of the federal securities laws.

EyePoint, Inc. shares opened down 70% after the Company disclosed that DURAVYU (vorolanib intravitreal insert) failed to meet the prespecified primary endpoint -- change in best-corrected visual acuity versus on-label aflibercept -- in the full dataset of the Phase 3 LUGANO trial for wet age-related macular degeneration. The clinical trial failure occurred despite the Company repeatedly describing the program as "derisked" across at multiple earnings calls from Q4 2024 through Q1 2026. On May 6, 2026, President and CEO Jay Duker stated, "We are confident that our clinically-rigorous, derisked and patient-centric approach will continue to reinforce DURAVYU's best-in-class potential." On June 9, he reiterated that they "remain quite confident and quite optimistic in the results, and we think we can make a difference for patients," while claiming the company was "underappreciated" at the time as a "derisked asset." The Company performed an ad hoc analysis excluding a 4% asymmetric patient cohort, but this did not remedy the failure of the prespecified analysis for investors or regulators. The investigation concerns whether EyePoint, Inc. adequately disclosed the risks of the LUGANO trial failing its primary endpoint and the details and risk profile of the asymmetric patient cohort ahead of the clinical trial results disclosure in August 2026.

If you suffered a loss on your EyePoint, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP